Likewise we found that expression levels of a wide range of molecules were affected in IFN-β-treated MS patients: 1) IL10 expression was significantly decreased in circulating CD4+ T-cells, which however was not associated with an decreased potential of antigen-specific CD4+ T-cells to express IL-10 ex vivo. The gene discussed is IFNB1; the disease is myeloid sarcoma.